A randomized controlled trial of levodopa in patients with Angelman syndrome. Issue 5 (25th September 2017)

• Record Type: Journal Article
• Authors: Tan, Wen‐Hann; Bird, Lynne M.; Sadhwani, Anjali; Barbieri‐Welge, Rene L.; Skinner, Steven A.; Horowitz, Lucia T.; Bacino, Carlos A.; Noll, Lisa M.; Fu, Cary; Hundley, Rachel J.; Wink, Logan K.; Erickson, Craig A.; Barnes, Gregory N.; Slavotinek, Anne; Jeremy, Rita; Rotenberg, Alexander; Kothare, Sanjeev V.; Olson, Heather E.; Poduri, Annapurna; Nespeca, Mark P.; Chu, Hillary C.; Willen, Jennifer M.; Haas, Kevin F.; Weeber, Edwin J.; Rufo, Paul A.
• Is Part Of: American journal of medical genetics. Volume 176:Issue 5(2018)
• Page Start: 1099
• Page End: 1107
• Publication Date: 2017-09-25
• Subjects: calcium‐calmodulin‐dependent protein kinase type 2 -- clinical trial -- developmental disabilities -- inborn genetic diseases -- rare disease -- UBE3A; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.38457
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract : Treatment for Angelman syndrome (AS) is currently limited to symptomatic interventions. A mouse model of AS has reduced calcium/calmodulin‐dependent kinase II activity due to excessive phosphorylation of specific threonine residues, leading to diminished long‐term potentiation. In a rat model of Parkinson disease, levodopa reduced phosphorylation of various proteins, including calcium/calmodulin‐dependent kinase II. Further studies demonstrated that AS mice treated with levodopa performed better on rotarod testing than untreated AS mice. We conducted a multi‐center double‐blind randomized placebo‐controlled 1‐year trial of levodopa / carbidopa with either 10 or 15 mg/kg/day of levodopa in children with AS. The outcome of this intervention was assessed using either the Bayley Scales of Infant Development or the Mullen Scales of Early Learning, as well as the Vineland Adaptive Behavior Scales, and the Aberrant Behavior Checklist. Of the 78 participants enrolled, 67 participants received study medication (33 on levodopa, 34 on placebo), and 55 participants (29 on levodopa, 26 on placebo) completed the 1‐year study. There were no clinically or statistically significant changes in any of the outcome measures over a 1‐year period comparing the levodopa and placebo groups. The number of adverse events reported, including the more serious adverse events, was similar in both groups, but none were related to treatment with levodopa. Our data demonstrate that levodopa is well‐tolerated by children with AS. However, in the doses used in this study, it failed to improve their neurodevelopment or behavioral outcome.